Wake Forest researchers have reprogrammed macrophages to target metastatic tumors in the brain, offering a potential new approach where conventional therapies struggle.
T cells have long held the title of the ideal immune cells for CAR therapy, but recent discoveries are opening new possibilities for other immune cells.